Antonio Craxi
Antonio Craxi
Full Professor of Gastroenterology and Internal Medicine
Verified email at unipa.it
TitleCited byYear
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonēales Jr, ...
New England Journal of Medicine 347 (13), 975-982, 2002
77892002
EASL clinical practice guidelines: management of hepatitis C
A Craxģ, G Dusheiko, R Flisiak
J hepatol 55 (2), 245-264, 2011
1955*2011
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
GL Davis, R Esteban-Mur, V Rustgi, J Hoefs, SC Gordon, C Trepo, ...
New England journal of medicine 339 (21), 1493-1499, 1998
14841998
Preoperative radiotherapy for resectable rectal cancer: a meta-analysis
C Cammą, M Giunta, F Fiorica, L Pagliaro, A Craxģ, M Cottone
Jama 284 (8), 1008-1015, 2000
9372000
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials
C Camma, F Schepis, A Orlando, M Albanese, L Shahied, F Trevisani, ...
Radiology 224 (1), 47-54, 2002
8792002
Statements from the Taormina expert meeting on occult hepatitis B virus infection
G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, ...
Journal of hepatology 49 (4), 652-657, 2008
8072008
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis
F Fiorica, D Di Bona, F Schepis, A Licata, L Shahied, A Venturi, AM Falchi, ...
Gut 53 (7), 925-930, 2004
6332004
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonēales Jr, ...
Journal of hepatology 43 (3), 425-433, 2005
6312005
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ...
Journal of hepatology 57 (4), 821-829, 2012
5482012
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised …
IM Jacobson, GJ Dore, GR Foster, MW Fried, M Radu, VV Rafalsky, ...
The Lancet 384 (9941), 403-413, 2014
5402014
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection
T Pollicino, G Squadrito, G Cerenzia, I Cacciola, G Raffa, A Craxı̀, ...
Gastroenterology 126 (1), 102-110, 2004
4502004
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C
S Petta, C Cammą, C Scazzone, C Tripodo, V Di Marco, A Bono, D Cabibi, ...
Hepatology 51 (4), 1158-1167, 2010
4442010
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
C Cammą, M Giunta, P Andreone, A Craxı̀
Journal of hepatology 34 (4), 593-602, 2001
4412001
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?
F Schepis, C Cammą, D Niceforo, A Magnano, S Pallio, M Cinquegrani, ...
Hepatology 33 (2), 333-338, 2001
4292001
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study
RG Simonetti, C Cammą, F Fiorello, M Cottone, M Rapicetta, L Marino, ...
Ann Intern Med 116 (2), 97-102, 1992
4171992
Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening
V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ...
Gastroenterology 150 (5), 1147-1159. e5, 2016
3702016
Non-alcoholic fatty liver disease pathogenesis: the present and the future
S Petta, C Muratore, A Craxi
Digestive and Liver Disease 41 (9), 615-625, 2009
3312009
Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.
F Tinč, S Magrin, A Craxģ, L Pagliaro
Journal of hepatology 13 (2), 192-199, 1991
3271991
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The Lancet Gastroenterology & Hepatology 2 (3), 161-176, 2017
3262017
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
T Poynard, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, ...
Gastroenterology 136 (5), 1618-1628. e2, 2009
3102009
The system can't perform the operation now. Try again later.
Articles 1–20